Low-density lipoprotein receptor-related protein 8

RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH

Retrieved on: 
Tuesday, November 15, 2022

PDAC is one of the most chemo-resistant and radio-resistant types of cancers due to the dense pancreatic connective tissue and the diversity of genetic mutations.

Key Points: 
  • PDAC is one of the most chemo-resistant and radio-resistant types of cancers due to the dense pancreatic connective tissue and the diversity of genetic mutations.
  • Our current therapeutic approaches for these cancers are invasive and fail meaningful results while adversely effects on the quality of life of our patients.
  • RadioMedix is serving as a Sponsor and manufacturer of the clinical doses of 68Ga-RMX-VH., said Dr. Izabela Tworowska, CSO of RadioMedix.
  • In addressing other unmet needs in oncology, RadioMedix is developing theranostic agents to treat brain tumors, and pancreatic ductal adenocarcinoma (PDAC).

Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab

Retrieved on: 
Wednesday, July 13, 2022

CAMBRIDGE, Mass., July 13, 2022 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that four new research updates were presented on abelacimab during the Venous Thromboembolism poster session at the ongoing International Society on Thrombosis and Haemostasis 2022 Congress in London, UK.

Key Points: 
  • "Coagulation is a complex multilayered process and the potential benefits of inhibiting Factor XI are becoming increasingly clear.
  • It demonstrated that abelacimab did not affect the level of antiplatelet inhibition achieved either by aspirin or ticagrelor confirming that abelacimab will not interfere with the benefits of these antiplatelet agents.
  • Abelacimab is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
  • Abelacimab targets the active domain of Factor XI, demonstrating dual inhibitory activity against both Factor XI and its activated form, Factor XIa.